299 related articles for article (PubMed ID: 16526983)
1. Active surveillance with selective delayed intervention for favorable risk prostate cancer: clinical experience and a 'number needed to treat' analysis.
Klotz LH; Nam RK
Can J Urol; 2006 Feb; 13 Suppl 1():48-55. PubMed ID: 16526983
[TBL] [Abstract][Full Text] [Related]
2. Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer.
Klotz L
Nat Clin Pract Urol; 2005 Mar; 2(3):136-42; quiz 1 p following 149. PubMed ID: 16474710
[TBL] [Abstract][Full Text] [Related]
3. Active surveillance with selective delayed intervention: walking the line between overtreatment for indolent disease and undertreatment for aggressive disease.
Klotz LH
Can J Urol; 2005 Feb; 12 Suppl 1():53-7; discussion 101-2. PubMed ID: 15780167
[TBL] [Abstract][Full Text] [Related]
4. Active surveillance with selective delayed intervention for favorable risk prostate cancer.
Klotz L
Urol Oncol; 2006; 24(1):46-50. PubMed ID: 16414494
[TBL] [Abstract][Full Text] [Related]
5. Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer.
Klotz L
Eur Urol; 2005 Jan; 47(1):16-21. PubMed ID: 15582244
[TBL] [Abstract][Full Text] [Related]
6. Active surveillance versus radical treatment for favorable-risk localized prostate cancer.
Klotz L
Curr Treat Options Oncol; 2006 Sep; 7(5):355-62. PubMed ID: 16904052
[TBL] [Abstract][Full Text] [Related]
7. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.
Choo R; Klotz L; Danjoux C; Morton GC; DeBoer G; Szumacher E; Fleshner N; Bunting P; Hruby G
J Urol; 2002 Apr; 167(4):1664-9. PubMed ID: 11912384
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.
Krakowsky Y; Loblaw A; Klotz L
J Urol; 2010 Jul; 184(1):131-5. PubMed ID: 20478589
[TBL] [Abstract][Full Text] [Related]
9. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
[TBL] [Abstract][Full Text] [Related]
10. Active surveillance for prostate cancer: for whom?
Klotz L
J Clin Oncol; 2005 Nov; 23(32):8165-9. PubMed ID: 16278468
[TBL] [Abstract][Full Text] [Related]
11. Active surveillance for low-risk prostate cancer: selection of patients and predictors of progression.
Dall'Era MA; Konety BR
Nat Clin Pract Urol; 2008 May; 5(5):277-83. PubMed ID: 18285752
[TBL] [Abstract][Full Text] [Related]
12. Expectant management with selective delayed intervention for favorable-risk prostate cancer.
Klotz LH; Choo R; Morton G; Danjoux C
Can J Urol; 2002 Jun; 9 Suppl 1():2-7. PubMed ID: 12121587
[TBL] [Abstract][Full Text] [Related]
13. [Management of prostate cancer with indolent biological potential: from watchful waiting to active surveillance].
Leibovici D; Lindner A; Stay K; Zisman A
Harefuah; 2006 Oct; 145(10):763-7, 781, 780. PubMed ID: 17111715
[TBL] [Abstract][Full Text] [Related]
14. Low-risk prostate cancer can and should often be managed with active surveillance and selective delayed intervention.
Klotz L
Nat Clin Pract Urol; 2008 Jan; 5(1):2-3. PubMed ID: 18043601
[No Abstract] [Full Text] [Related]
15. Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy.
Kulkarni GS; Lockwood G; Evans A; Toi A; Trachtenberg J; Jewett MA; Finelli A; Fleshner NE
Cancer; 2007 Jun; 109(12):2432-8. PubMed ID: 17497649
[TBL] [Abstract][Full Text] [Related]
16. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.
Roemeling S; Roobol MJ; Postma R; Gosselaar C; van der Kwast TH; Bangma CH; Schröder FH
Eur Urol; 2006 Sep; 50(3):475-82. PubMed ID: 16713065
[TBL] [Abstract][Full Text] [Related]
17. Active surveillance for favorable risk prostate cancer: rationale, risks, and results.
Klotz L
Urol Oncol; 2007; 25(6):505-9. PubMed ID: 18047961
[TBL] [Abstract][Full Text] [Related]
18. Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial.
Johansson E; Bill-Axelson A; Holmberg L; Onelöv E; Johansson JE; Steineck G;
Eur Urol; 2009 Feb; 55(2):422-30. PubMed ID: 18783877
[TBL] [Abstract][Full Text] [Related]
19. Radical prostatectomy for clinical stage T3a disease.
Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
[TBL] [Abstract][Full Text] [Related]
20. Active surveillance for good risk prostate cancer: rationale, method, and results.
Klotz LH
Can J Urol; 2005 Jun; 12 Suppl 2():21-4. PubMed ID: 16018828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
